Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 plus Cetrelimab vs Cetrelimab alone in muscle-invasive urothelial carcinoma prior to radical cystectomy
2020-005565-13Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC) comparing TAR-200 + Cetrelimab with Cetrelimab alone (2 arms). Primary endpoint: Pathologic complete response rate at radical cystectomy. Started Sep 2021; status: active.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2020-005565-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005565-13.